Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive entities : Astellas pharma inc save search
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-03-22 (Crawled : 12:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: -0.54%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 2.26%
H: 0.0%
C: -2.65%
chmp positive cancer treatment
Generalized Anxiety Disorder Treatment Market to Showcase Positive Growth During the Forecast Period (2023-2032), Assesses DelveInsight | Key Players - MindMed, VistaGen Therapeutics, Actavis, Takeda Pharmaceuticals, Bionomics
Published: 2023-10-30 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: -3.51%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -1.67%
H: 3.16%
C: 2.75%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.61%
H: 0.0%
C: 0.0%
positive treatment growth market
Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)
Published: 2023-10-13 (Crawled : 00:20) - biospace.com/
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: -1.86%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -2.78%
H: 0.04%
C: -0.57%
chmp positive
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
Published: 2023-09-18 (Crawled : 23:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -0.44%
H: 0.24%
C: 0.1%
positive topline results study
Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause
Published: 2023-06-28 (Crawled : 08:00) - biospace.com/
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 1.2%
H: 0.26%
C: -0.2%
positive treatment topline trial results
Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause
Published: 2023-06-27 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 1.2%
H: 0.26%
C: -0.2%
positive treatment topline trial results
Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series
Published: 2023-03-21 (Crawled : 22:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.57%
H: 1.35%
C: 0.43%
glow asco positive trial
Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers Symposium
Published: 2023-01-19 (Crawled : 15:20) - biospace.com/
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.2%
H: 0.0%
C: -0.46%
symposium trial asco positive
Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
Published: 2022-07-26 (Crawled : 11:00) - biospace.com/
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.06%
H: 0.71%
C: 0.45%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.75%
H: 4.37%
C: 1.94%
padcev treatment topline positive cancer
Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
Published: 2022-07-26 (Crawled : 09:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.06%
H: 0.71%
C: 0.45%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.75%
H: 4.37%
C: 1.94%
padcev treatment topline positive cancer
Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
Published: 2022-02-28 (Crawled : 15:00) - biospace.com/
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.3%
H: 0.47%
C: -1.13%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -0.44%
H: 2.24%
C: 0.83%
padcev positive cancer chmp
Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe Disease
Published: 2022-02-07 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -2.23%
H: 4.97%
C: 4.91%
at845 disease positive set
Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
Published: 2021-12-17 (Crawled : 13:30) - biospace.com/
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 1.37%
H: 0.0%
C: -1.84%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -2.69%
H: 0.0%
C: 0.0%
positive cancer chmp
Astellas to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia - from Diagnosis to Relapse - at 2021 American Society of Hematology Annual Meeting
Published: 2021-12-01 (Crawled : 14:30) - biospace.com/
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 3.97%
H: 0.0%
C: -3.85%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -2.8%
H: 3.17%
C: 1.06%
ema myeloid leukemia leukemia research positive diagnostic acute myeloid leukemia
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.